CD163 and renal carcinoma: In clinicopathological studies of malignant tumors using CD163 to detect M2-like TAMs, patients with glioma (Komohara et al., 2011b), follicular lymphoma (Clear et al., 2010), renal cancer (Komohara et al., 2011a), and pancreatic cancer (Kurahara et al., 2011) were shown to have poorer clinical prognosis in the presence of TAMs with a higher expression of CD163.